Rapid Micro Biosystems, Inc.

Print
General Information
Business:
We are an innovative life sciences technology company providing automated microbial quality control (MQC) to facilitate the efficient manufacturing as well as the fast and safe release of healthcare products such as biologics, vaccines, cell and gene therapies and sterile injectables. Our flagship Growth Direct platform automates and modernizes the antiquated manual microbial quality control or MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. Our customer base includes over half of the top 20 pharmaceutical companies as measured by revenue and 30% of globally approved cell and gene therapies. 
 
(Note: Rapid Micro Biosystems, Inc. upsized its IPO at pricing on July 14, 2021, to 7.92 million shares, up from 6.6 million shares in the prospectus, at $20 – the top of its $18-to-$20 price range – to raise $158.4 million.)
Industry: LABORATORY ANALYTICAL INSTRUMENTS
Employees: 160
Founded: 2006
Contact Information
Address 1001 Pawtucket Boulevard West, Suite 280 Lowell, Massachusetts 01854
Phone Number 978-349-3200
Web Address http://www.rapidmicrobio.com/
View Prospectus: Rapid Micro Biosystems, Inc.
Financial Information
Market Cap $734.73mil
Revenues $14.83 mil (last 12 months)
Net Income $-51.17 mil (last 12 months)
IPO Profile
Symbol RPID
Exchange NASDAQ
Shares (millions): 7.9
Price range $20.00 - $20.00
Est. $ Volume $158.4 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ Cowen and Company/ Stifel
CO-Managers -
Expected To Trade: 7/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change